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Abstract
Introduction Albumin administration in the critically ill has been
the subject of some controversy. We investigated the use of
albumin solutions in European intensive care units (ICUs) and its
relationship to outcome.
Methods In a cohort, multicenter, observational study, all
patients admitted to one of the participating ICUs between 1
May and 15 May 2002 were followed up until death, hospital
discharge, or for 60 days. Patients were classified according to
whether or not they received albumin at any time during their
ICU stay.
Results Of 3,147 admitted patients, 354 (11.2%) received
albumin and 2,793 (88.8%) did not. Patients who received
albumin were more likely to have cancer or liver cirrhosis, to be
surgical admissions, and to have sepsis. They had a longer
length of ICU stay and a higher mortality rate, but were also more
severely ill, as manifested by higher simplified acute physiology
score (SAPS) II and sequential organ failure assessment
(SOFA) scores than the other patients. A Cox proportional
hazard model indicated that albumin administration was
significantly associated with decreased 30-day survival.
Moreover, in 339 pairs matched according to a propensity
score, ICU and hospital mortality rates were higher in the
patients who had received albumin than in those who had not
(34.8 versus 20.9% and 41.3 versus 27.7%, respectively, both
p < 0.001).
Conclusion Albumin administration was associated with
decreased survival in this population of acutely ill patients.
Further prospective randomized controlled trials are needed to
examine the effects of albumin administration in sub-groups of
acutely ill patients.
Introduction
Albumin administration in the critically ill is controversial and
hotly debated, despite having been accepted and widely used
for more than 50 years. A meta-analysis by the Cochrane
group [1] published 5 years ago first put light to this fire, show-
ing an increased mortality in patients treated with albumin in
their analysis of 30 randomized controlled trials including
1,419 randomized patients. An accompanying editorial even
suggested that, based on these results, "the administration of
albumin should be halted" [2]. The Cochrane analysis was crit-
icized by a later meta-analysis [3] because it excluded, for var-
ious reasons, several trials that had shown reduced mortality
rates with albumin administration. When more studies were
included into the meta-analysis, an adverse effect of albumin
on mortality could no longer be demonstrated [3]. Both analy-
ses, however, have the limitation that the inclusion criteria
were very broad and the fluid regimen very different among the
included trials. In a recent randomized controlled study (the
Saline versus Albumin fluid Evaluation (SAFE) study) providing
data on nearly 7,000 patients randomized to receive either
CI = confidence interval; ICU = intensive care unit; SAFE = saline versus albumin fluid evaluation; SAPS = simplified acute physiology score; SOAP 
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albumin or normal saline as resuscitation fluid, there was no
difference in outcome between the two groups [4].
While randomized controlled trials such as the SAFE study
provide strong evidence for or against an intervention, epide-
miological studies allowing for multivariable analyses can pro-
vide useful additional information on the current use of albumin
and on associated outcomes. The Sepsis Occurrence in
Acutely ill Patients (SOAP) study did exactly this to determine
current intensive care unit (ICU) practice and the effects of
that practice on outcomes for various topics, including admin-
istration of albumin.
Methods
Study design
The SOAP study was a prospective, multicenter, observational
study designed to evaluate the epidemiology of sepsis as well
as other characteristics of ICU patients in European countries
and was initiated by a working group of the European Society
of Intensive Care Medicine. Institutional recruitment for partic-
ipation was by open invitation from the study steering commit-
tee. As this epidemiological observational study did not
require any deviation from routine medical practice, institu-
tional review board approval was either waived or expedited in
participating institutions and informed consent was not
required. All patients older than 15 years admitted to the par-
ticipating centers (see Acknowledgements below for a list of
participating countries and centers) between 1 May and 15
May 2002 were included. Patients were followed up until
death, hospital discharge, or for 60 days. Those who stayed in
the ICU for less than 24 hours for routine postoperative obser-
vation were excluded.
Data management
Data were collected prospectively using preprinted case
report forms. Detailed explanations of the aim of the study,
instructions for data collection, and definitions for various
important items were available for all participants via the Inter-
net [5] before starting data collection and throughout the
study period. The steering committee processed all queries
during data collection.
Data were entered centrally by medical personnel using the
SPSS v11.0 for Windows (SPSS Inc, Chicago, IL, USA). A
sample of 5% of data was re-entered by a different encoder
and revised by a third; a consistency of more than 99.5% per
variable and 98.5% per patient were observed during the
whole process of data entry. In cases of inconsistency, data
were verified and corrected. Daily frequency tables were
revised for all variables and the investigators were queried
w h e n  d a t a  v a l u e s  w e r e  e i t h e r  q u e s t i o n a b l e  o r  m i s s i n g  f o r
required fields. There was no data quality control at the data
collection level.
Data collection on admission included demographic data and
comorbidities. Clinical and laboratory data for the simplified
acute physiology (SAPS) II score [6] were reported as the
worst value within 24 hours after admission. Microbiological
and clinical infections were reported daily as well as the anti-
biotics administered. A daily evaluation of organ function,
based on a set of laboratory and clinical parameters according
to the sequential organ failure assessment (SOFA) score [7],
was performed, with the most abnormal value for each of the
six organ systems (respiratory, renal, cardiovascular, hepatic,
coagulation, and neurological) being collected on admission
and every 24 hours thereafter. For a single missing value, a
replacement was calculated using the mean value of the
results on either side of the absent result. When the first or last
values were missing the nearest value was carried backward
or forward, respectively. When more than one consecutive
result was missing, it was considered to be a missing value in
the analysis. Overall, missing data represented less than 6%
of collected data, and 2% of these values were replaced.
Definitions
Infection was defined as the presence of a pathogenic micro-
organism in a sterile milieu (such as blood, abscess fluid, cer-
ebrospinal or ascitic fluid), and/or clinically documented
infection, plus the administration of antibiotics. Sepsis was
defined according to the American College of Chest Physi-
cians/Society of Critical Care Medicine (ACCP/SCCM) con-
sensus conference definitions, by infection plus two systemic
inflammatory response syndrome (SIRS) criteria [8]. Organ
failure was defined as a SOFA score >2 for the organ in ques-
tion [9]. Severe sepsis was defined by sepsis plus at least one
organ failure. Mean fluid balance was calculated as the total
fluid balance during the ICU stay divided by the duration of
ICU stay in days.
Statistical methods
Data were analyzed using SPSS v11.0 for Windows (SPSS
Inc, Chicago, IL, USA). Descriptive statistics were computed
for all study variables. The Kolmogorov-Smirnov test was used
and stratified distribution plots were examined to verify the nor-
mality of distribution of continuous variables. Nonparametric
tests of comparison were used for variables evaluated as not
normally distributed. Difference testing between groups was
performed using the two-tailed t test, Mann-Whitney U test,
Chi square test, and Fisher exact test as appropriate. To deter-
mine the relative hazard of death due to albumin administra-
tion, a Cox proportional hazard model [10] was constructed
with time to death, right censored at 30 days as the dependent
factor and, as independent factors, age, sex, trauma, comor-
bidities on admission, SAPS II score on admission, the timing
of onset of albumin administration, use of other colloids and
blood products (red blood cells, fresh frozen plasma), and the
mean fluid balance, the degree of organ failure assessed by
the SOFA score, procedures (mechanical ventilation, pulmo-
nary artery catheter, renal replacement therapy), and theAvailable online http://ccforum.com/content/9/6/R745
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presence of sepsis syndromes on admission in patients who
did not receive albumin and at onset of albumin administration
in those who did, were also included as independent variables.
Covariates were selected and entered in the model if they
attained a p value <0.2 on a univariate basis. Seven countries
were included in the model, six being identified as a risk of
decreased survival and one with a favorable prognosis com-
pared with the others. A forward stepwise approach was per-
formed. Only significant variables were retained in the final
model. The time dependent covariate method [10] was used
to check the proportional hazard assumption of the model; an
extended Cox model was constructed, adding interaction
terms that involve time (for example, time dependent variables)
computed as the byproduct of time and individual covariates
in the model (time*covariate); individual time dependent cov-
ariates were introduced one by one and in combinations in the
extended model, none of which was found to be significant
(Wald chi-square statistic). The Cox proportional hazard
model was reconstructed, stratifying patients according to the
presence or absence of trauma or severe sepsis.
Propensity scores [11] were obtained through forward step-
wise logistic regression of patients' characteristics on albumin
infusion status [11-14], that is, albumin administration as the
dependent factor (Table 1). Variables were entered into the
model and removed at a cutoff p value of 0.2. The propensity
score was calculated as the probability based upon the final
model. A greedy matching technique [15] was used to match
individual patients who received albumin at any time with indi-
vidual patients without albumin based on propensity scores.
The best-matched propensity score was identical to five digits.
Once a match was made, the control patient was removed
from the pool. This process was then repeated using four-digit
matching, then three-digit matching, and so on. The process
proceeded sequentially to a single-digit match on propensity
score. If a match was not obtained at this point, the patient
who had received albumin was excluded. Baseline character-
istics were compared between the two matched groups with-
out comparing mortality and the process was repeated by
adding interactions to the logistic regression model involving
the unmatched covariates, including replacing it by its square
or multiplying two unmatched covariates [12]. Kaplan Meier
Table 1
Propensity score model
Coefficient SEM Wald Odds ratio (95% CI) p value
SOFA scorea 0.078 0.016 22.78 1.08 (1.05–1.12) <0.001
HES administrationb 0.591 0.129 21.10 1.81 (1.40–2.32) <0.001
RBC transfusionb 1.296 0.134 93.03 3.65 (2.81–4.76) <0.001
Cirrhosis 0.796 0.239 11.10 2.22 (1.39–3.54) 0.001
Medical admission -0.407 0.132 9.47 0.67 (0.51–0.86) 0.002
Cancer 0.451 0.167 7.32 1.57 (1.13–2.18) 0.007
Sepsisa 0.332 0.133 6.24 1.39 (1.074–1.81) 0.012
Hemofiltrationa 0.380 0.292 1.69 1.46 (0.83–2.59) 0.193
Hemodialysisa 0.525 0.368 2.04 1.69 (0.82–3.48) 0.154
Constant -0.591 0.543 1.19 NA 0.276
The basic model used to determine the propensity score was a multivariable, forward stepwise, logistic regression analysis with albumin 
administration as the dependent factor. aOn the day of onset of albumin administration in the albumin group and on admission in other patients. 
bAt any time during intensive care unit stay. CI, confidence interval; HES, hydroxyethyl starch; RBC, red blood cell; SEM, standard error of mean; 
SOFA, sequential organ failure assessment.
Figure 1
Bar chart representing the percentage of patients receiving albumin  infusions in the various contributing countries Bar chart representing the percentage of patients receiving albumin 
infusions in the various contributing countries. Only countries that 
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survival curves were plotted and compared using the signed
Log Rank test in the propensity score matched pairs. Another
Cox regression model was constructed as described above in
the group of matched pairs involving the propensity score as a
covariate. All statistics were two-tailed and a p value <0.05
was considered to be statistically significant.
Results
Of 3,147 patients, 354 (11.2%) received albumin and 2,793
(88.8%) did not. Figure 1 represents the proportion of patients
who received albumin in the 14 most represented countries. In
general, albumin administration was more commonly used in
the south of Europe. Albumin was administered during the first
24 hours following admission in 157 (44.4%) of those who
received it; only 34 patients (7.6%) received albumin after 7
days of admission.
Clinical data are presented in Table 2. Patients who received
albumin had the same mean age, but were more likely to have
cancer or liver cirrhosis, to be a surgical admission, and to
have sepsis than the patients who did not receive albumin.
They had a longer length of ICU stay and a higher ICU mortality
rate (35 versus 16%, p < 0.001), but were also more severely
ill, as manifested by higher SAPS II and SOFA scores than the
other patients. At the onset of albumin administration (Table
3), these patients had a higher degree of organ dysfunction
failure as manifested by higher SOFA scores and higher inci-
dence of sepsis and invasive procedures (mechanical ventila-
tion, pulmonary artery catheterization, and renal replacement
therapy) compared with these factors on admission in patients
who never received albumin during the ICU stay.
Table 2
Characteristics of the study group
All patients (n = 3,147) Stratifying according to albumin administration
Albumin (n = 354) No albumin (n = 2,793) p value
Age, mean ± SDa 61 ± 17 62 ± 15 60 ± 18 0.15
Male (%)b 1,920 (61.7%) 219 (62.4) 1,701 (61.6) 0.776
Chronic diseases (%)
COPD 340 (10.8) 38 (10.7) 302 (10.8) 0.964
Cancer 415 (13.2) 66 (18.7) 349 (12.5) <0.001
Heart failure 307 (9.8) 42 (11.9) 265 (9.5) 0.156
Diabetes 226 (7.2) 29 (8.2) 197 (7.1) 0.434
Liver cirrhosis 121 (3.8) 32 (9.0) 89 (3.2) <0.001
Hematologic cancer 69 (2.2) 13 (3.7) 56 (2.0) 0.053
HIV/AIDS 26 (0.9) 6 (1.7) 20 (0.7) 0.18
Surgical admission (%) 1,388 (44.1) 218 (61.6) 1,170 (41.9) <0.001
SAPS II score, mean ± SD 36.5 ± 17.1 41.5 ± 17.3 35.9 ± 17.0 <0.001
Admission SOFA score, mean ± SD 5.1 ± 3.8 6.9 ± 3.9 4.9 ± 3.8 <0.001
Infection (%) 1,177 (37.4) 225 (63.6) 952 (34.1) <0.001
On admission 777 (24.7) 140 (39.5) 637 (22.8) <0.001
Severe sepsis (%) 930 (29.6) 202 (57.1) 728 (26.1) <0.001
On admission 552 (17.5) 112 (31.6) 440 (15.8) <0.001
Septic shock (%) 462 (16.5) 144 (40.7) 318 (11.4) <0.001
On admission 243 (7.7) 62 (17.5) 181 (6.5) <0.001
ICU stay, median (IQ) 3.0 (1.7–6.9) 8.0 (3.1–17.8) 2.9 (1.6–6) <0.001
Hospital stay, median (IQ)c 15 (7–32) 27 (12–49) 14 (7–29) <0.001
ICU mortality (%)d 583 (18.5) 125 (35.3) 458 (16.4) <0.001
Hospital mortality (%)c 747 (23.7) 147 (41.5) 600 (21.3) <0.001
aNine missing. bThirty-five missing. cThirty-nine missing. dOne missing. ICU, intensive care unit; IQ, interquartile range; SAPS, simplified acute 
physiology score; SD, standard deviation; SOFA, sequential organ failure assessment.Available online http://ccforum.com/content/9/6/R745
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In the Cox proportional hazard model, albumin administration
was independently associated with a lower 30-day survival
(relative hazard 1.57, 95% confidence interval (CI) 1.11–2.22,
p = 0.012; Table 4). Albumin remained an independent risk of
lower 30-day survival when stratifying for trauma (n = 254) or
severe sepsis (n = 765) (Table 5). Moreover, in 339 pairs
matched according to a propensity score, ICU (34.8 versus
20.9%, p < 0.001) and hospital (41.3 versus 27.7%, p <
Table 3
Comparison of patients who received albumin and those who did not
All patients (n = 3,147) Albumin (n = 354) No albumin (n = 2,793) p value
SOFA score, mean ± SD 5.2 ± 3.9 7.2 ± 4.2 4.9 ± 3.8 <0.001
Sepsis syndromes (%)
Sepsis 765 (24.3) 128 (36.2) 637 (22.8) <0.001
Severe sepsis 549 (17.4) 109 (30.8) 440 (15.8) <0.001
Septic shock 241 (7.7) 60 (16.9) 181 (6.5) <0.001
Procedures (%)
Mechanical ventilation 1,853 (58.9) 269 (76.0) 1,584 (56.7) <0.001
Pulmonary artery 
catheter
378 (12.0) 74 (20.9) 304 (10.9) <0.001
Hemofiltration 82 (2.6) 23 (6.5) 59 (2.1) <0.001
Hemodialysis 57 (1.8) 13 (3.7) 44 (1.6) 0.005
Organ failure (%)
Respiratory 705 (22.4) 111 (31.4) 594 (21.3) <0.001
Cardiovascular 784 (24.9) 156 (44.1) 628 (22.5) <0.001
Coagulation 158 (5.0) 42 (11.9) 116 (4.2) <0.001
Hepatic 89 (2.8) 19 (5.4) 70 (2.5) 0.002
Renal 562 (17.9) 76 (21.5) 486 (17.4) 0.060
Neurological 681 (21.6) 71 (20.1) 610 (21.8) 0.443
Sequential organ failure assessment (SOFA) score, sepsis syndromes, procedures, and organ failure (SOFA > 2) in patients who did and did not 
receive albumin compared with admission values for patients who did not receive albumin.
Table 4
Cox proportional hazard model with time to death, right censored at 30 days, as dependent factor
All patients (n = 3,147) Propensity matched patients (n = 678)
Relative hazard (95% CI) p value Relative hazard (95% CI) p value
SAPS II scorea 1.04 (1.04–1.05) <0.001 1.02 (1.01–1.03) <0.003
SOFA scoreb 1.06 (1.03–1.08) <0.001 1.05 (1.01–1.10) 0.032
Medical admission 1.78 (1.25–2.21) <0.001 2.33 (1.63–3.31) <0.001
Age 1.01 (1.01–1.02) <0.001 1.02 (1.01–1.03) 0.003
Cirrhosis 2.23 (1.68–2.95) <0.001 1.91 (1.23–2.98) 0.004
Mean fluid balance 1.30 (1.24–1.37) 0.001 1.30 (1.19–1.42) <0.001
Hemofiltration 1.25 (1.04–1.50) 0.019 - -
Albumin administrationb 1.57 (1.11–2.22) 0.012 1.57 (1.19–2.07) 0.001
Propensity score 1.23 (1.12–1.67) 0.003 1.01 (1.01–1.02) 0.020
aOn admission. bOn the day of onset of albumin administration in the albumin group and on the day of admission for other patients. CI, confidence 
interval; SAPS, simplified acute physiology score; SOFA, sequential organ failure assessment.Critical Care    Vol 9 No 6    Vincent et al.
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0.001) mortality rates were higher in patients who received
albumin than in those who did not; the survival curves are
shown in Figure 2. In these matched pairs, albumin administra-
tion was associated with a decreased 30-day survival in a mul-
tivariable Cox proportional hazard analysis (relative hazard
1.57, 95% CI 1.19–2.07, p = 0.001; Table 4). Table 6 shows
the baseline characteristics of the propensity-matched
patients on admission on the basis of age, gender, comorbid-
ities, type of admission, SAPS II and SOFA scores, proce-
dures, and sepsis syndromes. Propensity scores were also
associated with a decreased 30-day survival, both in the whole
population and in the matched pairs.
Discussion
In this observational study, patients who received albumin had
higher ICU and hospital mortality rates than those who did not.
This may be expected, as albumin administration is generally
added to resuscitative fluids in very ill patients or patients with
hypoalbuminemia and/or edema. Hypoalbuminemia itself is an
independent predictor of an adverse outcome [16-18]. In the
present study, patients who received albumin were also more
severely ill, with a higher frequency of cancer, liver cirrhosis,
and sepsis, and significantly higher SAPS II scores. Independ-
ent of albumin administration, these patients, therefore, had a
higher risk of death than patients who did not receive albumin.
We applied two different methods to control for these con-
founding factors. Firstly, we included the confounding varia-
bles in a Cox proportional hazard model. Secondly, we
produced unbiased estimators of the effects of albumin
administration on mortality rates by using a propensity analy-
sis. In both analyses, the mortality rates after adjustment for
confounding factors were still higher in patients who received
albumin than in those who did not. Therefore, the
administration of albumin was associated with higher mortality
independent of those comorbid conditions included in our sta-
tistical models.
Although a prospective, controlled randomized clinical trial is,
of course, the optimal means of demonstrating cause and
effect, epidemiological studies with adequate multivariable
analysis can provide valuable information. A similar approach
has been taken to show that aspirin administration may reduce
complications after coronary artery bypass grafting [19]. One
must, however, remember that a multivariable analysis cannot
take all factors into account, so that other unidentified factors
in the patients who received albumin may have influenced the
results. Nevertheless, many factors, including comorbid dis-
eases, were included in the analysis due to the epidemiologi-
cal nature of this study. Regional factors may also influence
results and, indeed, there were considerable regional varia-
tions, with albumin generally being used more commonly in the
south of Europe; however, we corrected for regional differ-
ences in our multivariable model.
The SOAP study was not originally designed to specifically
address questions regarding albumin administration in the
ICU. This analysis, therefore, has some limitations in addition
to those of a multivariable analysis. First, the indications for
albumin administration were not recorded. Second, serum
albumin levels were not measured and it thus remains unclear
whether albumin levels were successfully corrected in patients
treated with albumin. Indeed, there are data suggesting that
the use of albumin in patients with hypoalbuminemia may be
beneficial. In a recently published meta-analysis [16], nine
studies addressing morbidity in critically ill patients after cor-
rection of hypoalbuminemia were identified. There was a trend
towards reduced morbidity in patients where hypoalbumine-
mia was corrected (odds ratio 0.74; 95% CI 0.41–1.60). The
meta-analysis also suggested that albumin levels need to
reach more than 30 g/l before albumin replacement becomes
effective [16]; only four of the nine studies achieved this goal.
It should be pointed out that three of the four studies were
undertaken in pediatric patients. Another recent meta-analysis
noted a trend towards reduced morbidity in hypoalbuminemic
patients who received albumin (relative risk 0.92; 95% CI
0.77–1.08) [20]. Nevertheless, it remains unproven whether
Table 5
Relative risk of albumin administration based upon a Cox 
proportional hazard analysisa stratified by severe sepsisb and 
trauma
n Relative hazard (95% CI) p value
No trauma 2,893 1.32 (1.09–1.60) 0.005
Trauma 254 2.58 (1.05–6.04) 0.035
No severe sepsis 2,382 1.29 (1.01–1.66) 0.048
Severe sepsis 765 1.01 (1.13–2.00) 0.006
aMultivariable, forward, stepwise with time to mortality, right censored 
at 30 days, as the dependent factor. bOn the day of albumin 
administration in the albumin group and on admission in others.
Figure 2
Kaplan-Meier survival curves in patients who received albumin (lower  curve) and their propensity matched pairs without albumin  administration Kaplan-Meier survival curves in patients who received albumin (lower 
curve) and their propensity matched pairs without albumin 
administration.Available online http://ccforum.com/content/9/6/R745
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Table 6
Patient characteristics by albumin status for the propensity matched patients
Albumin (n = 339) No albumin (n = 339) p value
Age, mean ± SD 62.6 ± 15.1 62.6 ± 17.1 0.365
Male gender (%) 221 (62.2) 206 (60.8) 0.693
Chronic diseases (%)
COPD 37 (10.9) 33 (9.7) 0.614
Cancer 61 (18.0) 62 (18.3) 0.921
Heart failure 40 (11.8) 43 (12.7) 0.725
Diabetes 27 (8.0) 34 (10.0) 0.347
Liver cirrhosis 30 (8.8) 26 (7.7) 0.577
Hematologic cancer 12 (3.5) 10 (2.9) 0.665
HIV/AIDS 5 (1.5) 7 (2.1) 1.000
Surgical admissions (%) 208 (61.4) 215 (63.4) 0.579
SAPS II score, mean ± SD 41.7 ± 17.2 41.6 ± 18.1 0.664
SOFA score, mean ± SDa 7.1 ± 4.1 6.7 ± 4.4 0.126
Organ failurea
Respiratory 106 (31.3) 100 (29.5) 0.616
Hepatic 16 (4.7) 15 (4.4) 0.854
Coagulation 39 (11.5) 27 (8.0) 0.120
Renal 72 (21.2) 71 (20.9) 0.925
CNS 70 (20.6) 79 (23.3) 0.404
Cardiovascular 147 (43.4) 146 (43.1) 0.939
Sepsis syndromes (%)a
Sepsis 120 (35.4) 132 (38.9) 0.441
Severe sepsis 103 (30.4) 101 (29.8) 0.867
Septic shock 57 (16.8) 50 (14.7) 0.461
Procedures (%)a
Mechanical ventilation 259 (76.4) 255 (75.5) 0.720
Pulmonary artery catheter 71 (20.9) 58 (17.1) 0.203
Hemofiltration 23 (6.8) 17 (5.0) 0.335
Hemodialysis 11 (3.2) 9 (2.7) 0.650
Mean fluid balance ± SD 0.2 ± 1.3 0.2 ± 1.4 0.474
Trauma 18 (5.3) 14 (4.1) 0.446
ICU mortality (%) 118 (34.8) 71 (20.9) <0.001
Hospital mortality (%) 140 (41.3) 94 (27.7) <0.001
aOn the day of albumin administration in the albumin group and on admission in the others. CNS, central nervous system; ICU, intensive care unit; 
IQ, interquartile range; SAPS, simplified acute physiology score; SD, standard deviation; SOFA, sequential organ failure assessment; COPD: 
chronic obstructive pulmonary disease.Critical Care    Vol 9 No 6    Vincent et al.
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an improvement in morbidity translates into an improvement in
survival.
The reason for an increased mortality in patients who received
albumin cannot be identified from our study. Albumin has well-
recognized, potentially important functions in the critically ill,
including maintenance of colloid oncotic pressure, binding
capacity for drugs and other substances, and scavenging of
oxygen free radicals [21]. Starling's principle may not appro-
priately reflect the microcirculation in critically ill patients, how-
ever, especially under conditions of capillary leakage, as may
happen in sepsis or burns [22]. Other possible negative
effects of albumin administration may include myocardial
depression due to decreased ionic calcium [23], and impaired
renal function [24,25]. Furthermore, albumin has anti-throm-
botic properties that might be detrimental in some patients
[1,26].
The recently completed, randomized controlled SAFE study
[4] showed no differences in outcome in critically ill patients
requiring fluid repletion who were treated with 4% albumin
compared to those treated with saline. The SAFE study was
without doubt a well-conducted study that answered ade-
quately the question it asked, that is, that in a heterogeneous
population of critically ill patients albumin does not seem to
have harmful effects. However, albumin was given, often tran-
siently, as part of a fluid challenge and a 4% albumin solution
was used. Therefore, a number of patients received only small
amounts of albumin that were unlikely to influence outcome.
Conclusion
Albumin may indeed be safe when used as a resuscitation fluid
(as shown by the SAFE study), but our results suggest that it
may not be safe all of the time in all critically ill patients. We
believe further studies, such as the present, are needed to
generate hypotheses and encourage further research to fully
clarify the role of albumin in our ICUs.
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